Abstract Number: 1828 • 2012 ACR/ARHP Annual Meeting
Smoking Is Associated with Worse and More Widespread Pain, Worse Fatigue, General Health and Quality of Life in a Swedish Population Based Cohort of Patients with Psoriatic Arthritis
Background/Purpose: Smoking has been found to be associated with an increased risk of developing psoriatic arthritis (PsA). The purpose of this study was analyse possible…Abstract Number: 1829 • 2012 ACR/ARHP Annual Meeting
Cost of Etanercept, Adalimumab, and Infliximab in Patients with Rheumatoid Arthritis with Employer Provided Health Insurance
Background/Purpose: Tumor Necrosis Factor Inhibitors (TNFi) are the mainstay of treatment for rheumatoid arthritis (RA) in patients with moderate to severe disease. The three most…Abstract Number: 1830 • 2012 ACR/ARHP Annual Meeting
Drugs Are the Major Cost Driver of Rheumatoid Arthritis As Soon As the First Year of the Disease: An Economic Analysis Based On the Espoir Cohort Data
Background/Purpose: Many studies have explored the economic burden of established RA but few data are available about the determinants of costs in early rheumatoid arthritis…Abstract Number: 1831 • 2012 ACR/ARHP Annual Meeting
Evaluation of the Cost-Effectiveness of Rheumatoid Arthritis Treatment with Biologic Agents Using the IORRA Cohort Database
Background/Purpose: Rheumatoid arthritis (RA), a chronic inflammatory disorder, causes a significant decrease in quality of life. Recently developed biologic agents (BAs) have caused a considerable…Abstract Number: 1832 • 2012 ACR/ARHP Annual Meeting
Evaluating the Cost-Effectiveness of Personalized Treatment with Adalimumab Using Serum Drug Levels in Rheumatoid Arthritis Patients
Background/Purpose: The high costs of biologicals warrant a rational use of these drugs, preferably by tailoring them to the individual patient. The objective was to…Abstract Number: 1833 • 2012 ACR/ARHP Annual Meeting
Healthcare Costs in Psoriatic Arthritis Patients Newly Initiated On a Biologic Disease-Modifying Anti-Rheumatic Drug or Methotrexate
Background/Purpose: Several treatment options are available for psoriatic arthritis (PsA) patients (pts). The healthcare cost associated with the management of PsA pts varies depending on…Abstract Number: 1834 • 2012 ACR/ARHP Annual Meeting
Utilization and Expected Cost of Rheumatoid Arthritis Patients Treated with Golimumab: A Specialty Pharmacy Perspective
Background/Purpose: Golimumab is a 50 mg, once-monthly, patient-administered anti-tumor necrosis factor alpha (anti-TNF) therapy indicated for moderate to severe rheumatoid arthritis (RA), active psoriatic arthritis,…Abstract Number: 1835 • 2012 ACR/ARHP Annual Meeting
Prescription of Biologics in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS) in 4 Norwegian Regions 2002-2011: A Study of Prescription Rates and Baseline Disease Activity
Background/Purpose: Biologics have constituted a major advance in the treatment of RA, PsA and AS. In Norway access to these therapies has been good since…Abstract Number: 1836 • 2012 ACR/ARHP Annual Meeting
Early Versus Delayed Initiation of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Background/Purpose: Studies from a number of countries suggest that the time between symptom onset and initiation of DMARD therapy in RA patients is still longer…Abstract Number: 1837 • 2012 ACR/ARHP Annual Meeting
Which Rheumatoid Arthritis, Ankylosing Spondylitis and Juvenile Idiopathic Arthritis Patients Initiate Anti-TNFá Therapy?
Background/Purpose: Comprehensive guidelines for anti-TNFα were proposed in 2005 by the French Society for Rheumatology (SFR) in France; they did not include any economic considerations…Abstract Number: 1838 • 2012 ACR/ARHP Annual Meeting
10-Year Trends in the Use of Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Biologic Agents in Rheumatoid Arthritis: A National Veteran Affairs Study
Background/Purpose: It is unclear how recommendations for disease modifying anti-rheumatic drugs (DMARDs) & biological agents in treatment of Rheumatoid Arthritis (RA) have influenced their use…Abstract Number: 1798 • 2012 ACR/ARHP Annual Meeting
Macrophage Migration Inhibitory Factor Regulates Dual-Specificity Phosphatases Via Glucocorticoid Induced Leucine Zipper
Background/Purpose: Macrophage migration inhibitory factor (MIF) plays a pivotal role in promotion of inflammatory diseases such as rheumatoid arthritis (RA). MIF has previously been shown…Abstract Number: 1799 • 2012 ACR/ARHP Annual Meeting
ONO-4059 – A Novel Small Molecule Bruton’s Tyrosine Kinase (Btk) Inhibitor, Suppresses Osteoclast Differentiation and Activation
Background/Purpose: Bruton’s tyrosine kinase (Btk) is primarily expressed in B cells, mast cells, platelets, myeloid cells and osteoclasts. Osteoclast differentiation is regulated by signaling pathways…Abstract Number: 1800 • 2012 ACR/ARHP Annual Meeting
Macrophages in Hypoxic Rheumatoid Joints Preferentially Express Hypoxia Inducible Transcription Factor-2
Background/Purpose: In rheumatoid arthritis (RA), the influx of inflammatory cells as well as the aggressive proliferation of fibroblast-like synovial cells (FLS) outstrips the oxygen supply…Abstract Number: 1801 • 2012 ACR/ARHP Annual Meeting
Biological Roles of C5orf30 in Rheumatoid Arthritis
Background/Purpose: A recent genome wide association study identified the variant rs26232 in the first exon of an uncharacterized gene C5orf30. In addition, this variant is…